Skip to main content
Erschienen in: World Journal of Surgical Oncology 1/2016

Open Access 01.12.2016 | Case report

Perivascular epithelioid cell tumor of the descending colon mimicking a gastrointestinal stromal tumor: a case report

verfasst von: Ryuta Iwamoto, Tatsuki R. Kataoka, Ayako Furuhata, Kazuo Ono, Seiichi Hirota, Kenji Kawada, Yoshiharu Sakai, Hironori Haga

Erschienen in: World Journal of Surgical Oncology | Ausgabe 1/2016

Abstract

Background

We present a case of perivascular epithelioid cell tumor (PEComa), which clinically and histologically mimics a gastrointestinal stromal tumor (GIST).

Case presentation

A 42-year-old woman was found to have a mass in the left flank during her annual medical checkup. Computed tomography examination revealed a submucosal tumor of the descending colon. Surgeons and radiologists suspected that the lesion was a GIST, and left hemicolectomy was performed without biopsy. Microscopic examination showed that the lesion was composed of spindle and epithelioid cells, which were immunohistochemically negative for c-kit and positive for platelet-derived growth factor receptor (PDGFR) α. Initial diagnosis of PDGFRα-positive GIST was made. However, gene analysis did not reveal mutations in PDGFRα. Additional immunohistochemistry showed that tumor cells were positive for human melanin black 45 (HMB45), melanA, and the myogenic marker calponin. A final diagnosis of PEComa was made.

Conclusion

PEComa should be included in the differential diagnosis of PDGFRα-positive spindle cell tumors in the wall of the gastrointestinal tract.
Abkürzungen
DOG1
Discovered on GIST-1
GIST
Gastrointestinal stromal tumor
HMB45
Human melanin black 45
MITF
Microphthalmia-associated transcription factor
PDGFR
Platelet-derived growth factor receptor
PEComa
Perivascular epithelioid cell tumor
TFE3
Transcriptional factor E3

Background

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor in the walls of the gastrointestinal tract [1]. GISTs typically harbor gain-of-function type mutations in the KIT genes [2], and GISTs without KIT mutations have gain-of-function type mutations in the platelet-derived growth factor receptor (PDGFR) α genes [3]. Expression of the two genes is mutually exclusive [13]. Perivascular epithelioid cell tumor (PEComa) is a less common mesenchymal tumor, expressing melanocytic and myogenic markers such as actin, desmin, calponin, human melanin black (HMB) 45, melanA, and microphthalmia-associated transcription factor (MITF) [4]. PEComa can occur in any organs, but is rarely detected in the gastrointestinal wall [5]. Herein, we report a case of PDGFRα-positive PEComa arising in the wall of the descending colon.

Case presentation

A 42-year-old woman underwent abdominal ultrasonography during her annual medical checkup and a mass in her left flank region was identified. She was admitted to the hospital for further examination. A computed tomography scan and endoscopic examination revealed a submucosal tumor in the wall of the descending colon. Systemic magnetic resonance imaging and positron emission tomography scans did not show any other lesions. The lesion was suspected to be a colonic GIST and left hemicolectomy was performed. Upon macroscopic examination, the tumor was 5 cm in the greatest dimension, well-circumscribed but uncapsulated, and extended from the muscular propria into the subserosa (Fig. 1a). The cut surface was hemorrhagic and necrotic (Fig. 1b). Microscopically, the tumor cells consisted of spindle and epithelioid cells with a granular cytoplasm (Fig. 2a). Based on the clinical diagnosis of GIST, a panel of immunohistochemistry including KIT, PDGFRα, discovered on GIST-1 (DOG1), CD34, S100, desmin, and Ki67 were performed. The tumor cells were positive for PDGFRα (Fig. 2b) and negative for KIT (Fig. 2c), DOG1 (Fig. 2d), CD34, S100, and desmin. The Ki-67 index was 3% (Fig. 2e). We initially suspected the tumor to be a PDGFRα-positive GIST. Mutational analysis did not reveal any mutation in PDGFRα or KIT, and suggested the possibility of a low-grade tumor other than GIST. Upon further examination, the tumor cells were found to be positive for HMB45 (Fig. 2f) and calponin (Fig. 2g), and negative for melanA, MITF, SOX10, and actin. These results were compatible with PEComa. This tumor was immunohistochemically negative for TFE3 (Fig. 2h), but did not show rearrangement of TFE3 in fluorescence in situ hybridization (FISH) (data not shown). The patient was alive without recurrence 5 months after the resection.

Discussion

PEComa is rare in the gastrointestinal tract. To the best of our knowledge, only 36 cases of gastrointestinal PEComa have been reported sporadically [6, 7]. Doyle et al. performed a clinicopathologic study of 35 cases of gastrointestinal PEComa [5]. The current case shows similarities with previously reported cases of gastrointestinal PEComa, in terms of the clinicopathological features and immunological profile. GIST does not show immunoreactivity for melanocytic markers [8], and expression of HMB45 is important to support the diagnosis of PEComa. Metastatic melanoma is positive for HMB45, but is also positive for S100 protein and lacks expression of myogenic markers such as calponin. Some cases of PEComa show gene rearrangement involving TFE3, and strong nuclear TFE3 expression [4, 5]. In our case, TFE3 rearrangement was not detected by FISH. This result is not incompatible with a diagnosis of PEComa because most gastrointestinal PEComas are negative for TFE3 [5]. Thus, TFE3 status may not be a diagnostic clue in gastrointestinal PEComa.
The tumor cells in our case were partly epithelioid and immunohistochemically PDGFRα-positive. These phenotypes were thought to be compatible with the initial diagnosis of GISTs with a PDGFRα mutation [3, 9]. However, GISTs with a PDGFRα mutation most commonly arise in the stomach [9, 10], and the tumor is typically DOG1-positive [11, 12]. In contrast to the case of GISTs, PDGFRα positivity and mutations in PDGFRα genes have not been reported in PEComas, to the best of our knowledge. The status of PDGFRα in PEComa should be further studied to diagnose PDGFRα-positive mesenchymal tumors in the gastrointestinal tract. Both GISTs and PEComas are treated with surgical resection and chemotherapy. GISTs are susceptible to the tyrosine kinase inhibitor imatinib [10], although PEComas are susceptible to another inhibitor, sirolimus [13]. Therefore, distinguishing between GISTs and PEComas would be important for appropriate administration of kinase inhibitors.

Conclusion

PEComa should be included in the differential diagnosis of mesenchymal tumors in the wall of the gastrointestine, even though tumor cells are immunohistochemically PDGFRα-positive. Mutational analysis should be performed to confirm the diagnosis of GIST, even though PDGFRα is immunohistochemically positive.

Acknowledgments

The authors thank Ms. Ijiri K (Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan) for her secretarial assistance.

Funding

TRK was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan (15K08362).

Availability of data and materials

All data on which the conclusions of this case report are included in this manuscript.

Authors’ contributions

RI, TRK, AF, KO, SH, and HH were all involved in this report’s conception and coordination, and helped to draft the manuscript. Additionally, all authors read and approved the final version of the manuscript.

Competing interests

The authors declare that they have no competing interests.
The patient signed the Kyoto University Hospital Informed Consent Form for the Non-therapeutic Use of Histopathological Materials, and the signed forms have been uploaded into her electronic health record.
This case report does not require ethical approval.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Hirota S, Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol Int. 2006;56:1–9.CrossRefPubMed Hirota S, Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol Int. 2006;56:1–9.CrossRefPubMed
2.
Zurück zum Zitat Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80.CrossRefPubMed Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80.CrossRefPubMed
3.
Zurück zum Zitat Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, Kitamura Y. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 2003;125:660–7.CrossRefPubMed Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, Kitamura Y. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 2003;125:660–7.CrossRefPubMed
4.
Zurück zum Zitat Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F. PEComas: the past, the present and the future. Virchows Arch. 2008;452:119–32.CrossRefPubMed Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F. PEComas: the past, the present and the future. Virchows Arch. 2008;452:119–32.CrossRefPubMed
5.
Zurück zum Zitat Doyle LA, Hornick JL, Fletcher CD. PEComa of the gastrointestinal tract: clinicopathologic study of 35 cases with evaluation of prognostic parameters. Am J Surg Pathol. 2013;37:1769–82.CrossRefPubMed Doyle LA, Hornick JL, Fletcher CD. PEComa of the gastrointestinal tract: clinicopathologic study of 35 cases with evaluation of prognostic parameters. Am J Surg Pathol. 2013;37:1769–82.CrossRefPubMed
6.
Zurück zum Zitat Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, Fletcher JA, Fletcher CD. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2014;28:889–94.CrossRef Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, Fletcher JA, Fletcher CD. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2014;28:889–94.CrossRef
7.
Zurück zum Zitat Liegl-Atzwanger B, Fletcher JA, Fletcher CD. Gastrointestinal stromal tumors. Virchows Arch. 2010;456:111–27.CrossRefPubMed Liegl-Atzwanger B, Fletcher JA, Fletcher CD. Gastrointestinal stromal tumors. Virchows Arch. 2010;456:111–27.CrossRefPubMed
8.
Zurück zum Zitat West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2014;165:107–13.CrossRef West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2014;165:107–13.CrossRef
9.
Zurück zum Zitat Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009;33:1401–8.CrossRefPubMed Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009;33:1401–8.CrossRefPubMed
10.
Zurück zum Zitat Chen Z, Shi H, Peng J, Yuan Y, Chen J, Song W. Perivascular epithelioid cell tumor in the duodenum: challenge in differential diagnosis. Int J Clin Exp Pathol. 2015;8:8555–62.PubMedPubMedCentral Chen Z, Shi H, Peng J, Yuan Y, Chen J, Song W. Perivascular epithelioid cell tumor in the duodenum: challenge in differential diagnosis. Int J Clin Exp Pathol. 2015;8:8555–62.PubMedPubMedCentral
11.
Zurück zum Zitat Lu B, Wang C, Zhang J, Kuiper RP, Song M, Zhang X, Song S, van Kessel AG, Iwamoto A, et al. Perivascular epithelioid cell tumor of gastrointestinal tract: case report and review of the literature. Medicine (Baltimore). 2015;94:e393.CrossRef Lu B, Wang C, Zhang J, Kuiper RP, Song M, Zhang X, Song S, van Kessel AG, Iwamoto A, et al. Perivascular epithelioid cell tumor of gastrointestinal tract: case report and review of the literature. Medicine (Baltimore). 2015;94:e393.CrossRef
12.
Zurück zum Zitat Wong NA, Melegh Z. Gastrointestinal stromal tumours can express CD10 and epithelial membrane antigen but not oestrogen receptor or HMB45. Histopathology. 2011;59:781–5.CrossRefPubMed Wong NA, Melegh Z. Gastrointestinal stromal tumours can express CD10 and epithelial membrane antigen but not oestrogen receptor or HMB45. Histopathology. 2011;59:781–5.CrossRefPubMed
13.
Zurück zum Zitat Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358:140–51. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358:140–51.
Metadaten
Titel
Perivascular epithelioid cell tumor of the descending colon mimicking a gastrointestinal stromal tumor: a case report
verfasst von
Ryuta Iwamoto
Tatsuki R. Kataoka
Ayako Furuhata
Kazuo Ono
Seiichi Hirota
Kenji Kawada
Yoshiharu Sakai
Hironori Haga
Publikationsdatum
01.12.2016
Verlag
BioMed Central
Erschienen in
World Journal of Surgical Oncology / Ausgabe 1/2016
Elektronische ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-016-1046-7

Weitere Artikel der Ausgabe 1/2016

World Journal of Surgical Oncology 1/2016 Zur Ausgabe

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.